Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells

The development of drugs to treat cancer is hampered by the inefficiency of translating pre-clinical in vitro monoculture and mouse studies into clinical benefit. There is a critical need to improve the accuracy of evaluating pre-clinical drug efficacy through the development of more physiologically...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lab on a chip Jg. 19; H. 7; S. 1193
Hauptverfasser: Gioeli, Daniel, Snow, Chelsi J, Simmers, Michael B, Hoang, Stephen A, Figler, Robert A, Allende, J Ashe, Roller, Devin G, Parsons, J Thomas, Wulfkuhle, Julia D, Petricoin, Emanuel F, Bauer, Todd W, Wamhoff, Brian R
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 27.03.2019
Schlagworte:
Biomimetics - methods
Carcinoma, Pancreatic Ductal - pathology
Cell Proliferation - drug effects
Humans
Tumor Microenvironment - drug effects
ISSN:1473-0189, 1473-0189
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The development of drugs to treat cancer is hampered by the inefficiency of translating pre-clinical in vitro monoculture and mouse studies into clinical benefit. There is a critical need to improve the accuracy of evaluating pre-clinical drug efficacy through the development of more physiologically relevant models. In this study, a human triculture 3D in vitro tumor microenvironment system (TMES) was engineered to accurately mimic the tumor microenvironment. The TMES recapitulates tumor hemodynamics and biological transport with co-cultured human microvascular endothelial cells, pancreatic ductal adenocarcinoma, and pancreatic stellate cells. We demonstrate that significant tumor cell transcriptomic changes occur in the TMES that correlate with the in vivo xenograft and patient transcriptome. Treatment with therapeutically relevant doses of chemotherapeutics yields responses paralleling the patients' clinical responses. Thus, this model provides a unique platform to rigorously evaluate novel therapies and is amenable to using patient tumor material directly, with applicability for patient avatars.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1473-0189
1473-0189
DOI:10.1039/c8lc00755a